Auswertung des Patient-Reported Outcomes Measurement Information System (PROMIS)-29 v2.1 für Frauen nach der Geburt
There is no widely used, statistically validated assessment for physical and mental health for the short- to medium-term in a postpartum population. PROMIS-29 has been validated for the assessment of these factors in a generic population, but has not been specifically evaluated for use with postpartum women.
This study is a longitudinal, single center observational cohort study designed to evaluate the reliability of the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 v2.1 survey in a postpartum population. PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living. While this survey has shown utility in other populations, it has yet to be assessed in an obstetric population. The investigators plan to recruit patients who are recently postpartum from vaginal or cesarean delivery to complete virtual surveys at defined time points (0, 2, 6, and 12 weeks after delivery). The investigators will subject survey data to statistical measures of validity and reliability comparing with contemporaneously collected surveys of established metrics for quality of life (WHOQoLBREF) and general (global) state of health (numerical rating score 1-100).
The hypothesis is that the PROMIS-29 v2.1 questionnaire is a statistically valid and reliable means of assessing physical and mental health in a postpartum population.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G1X5
- Mount Sinai Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Patients who deliver vaginally or by scheduled cesarean section at Mount Sinai Hospital.
Beschreibung
Inclusion Criteria:
- 18 years old and over
- singleton births
- 37 or more weeks gestational age
- multiparous or nulliparous patients
- spontaneous vaginal delivery or scheduled cesarean delivery with labor analgesia or neuraxial anesthesia
- give informed written consent
Exclusion Criteria:
- refusal to take part
- are unable to give or have withdrawn consent
- patients unable to communicate fluently in English
- patients who are less than 18 years old
- patients who had fetal demise or severely morbid fetal conditions such as intubation, cooling, expected surgical correction of congenital anomaly during hospitalization (although NICU admissions will be included)
- patients who were admitted in ICU
- patients who had failed neuraxial analgesia such as replaced epidurals or failed spinal requiring conversion to general anesthesia
- patients who had general anesthesia for cesarean delivery as defined by "GETA", including sedatives and deep sedation if not intubated
- patients who had intrapartum cesarean or had assisted/operative (i.e. vacuum, forceps) vaginal delivery.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Vaginal delivery
Patients who have vaginal deliveries with neuraxial labour analgesia. |
PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living.
Andere Namen:
The WHOQOL-BREF is a 26-item version of the 100-item WHOQOL-100 quality of life measure that addresses four quality of life domains: physical health, psychological health, social relationships and environment.
Andere Namen:
The EQ-5D-3L1 is a generic measure of health status consisting of two parts. The first part assesses health in five dimensions: MOBILITY, SELFCARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY/DEPRESSION. The second part of the questionnaire consists of a VAS on which the patient rates their perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).
Andere Namen:
|
|
Cesarean delivery
Patients who have a scheduled cesarean delivery with neuraxial anesthesia. |
PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living.
Andere Namen:
The WHOQOL-BREF is a 26-item version of the 100-item WHOQOL-100 quality of life measure that addresses four quality of life domains: physical health, psychological health, social relationships and environment.
Andere Namen:
The EQ-5D-3L1 is a generic measure of health status consisting of two parts. The first part assesses health in five dimensions: MOBILITY, SELFCARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY/DEPRESSION. The second part of the questionnaire consists of a VAS on which the patient rates their perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System) survey score
Zeitfenster: 24 hours
|
The PROMIS survey score at 24 hours postpartum |
24 hours
|
|
WHOQoLBREF (World Health Organization Quality of Life Brief Version) survey score
Zeitfenster: 24 hours
|
The WHOQoLBREF survey score at 24 hours postpartum |
24 hours
|
|
EQ-5D-3L1 (not an acronym) survey score
Zeitfenster: 24 hours
|
The EQ-5D-3L1 survey score at 24 hours postpartum |
24 hours
|
|
PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System) survey score
Zeitfenster: 2 weeks
|
The PROMIS survey score at 2 weeks postpartum |
2 weeks
|
|
WHOQoLBREF (World Health Organization Quality of Life Brief Version) survey score
Zeitfenster: 2 weeks
|
The WHOQoLBREF survey score at 2 weeks postpartum |
2 weeks
|
|
EQ-5D-3L1 (not an acronym) survey score
Zeitfenster: 2 weeks
|
The EQ-5D-3L1 survey score at 2 weeks postpartum |
2 weeks
|
|
PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System) survey score
Zeitfenster: 6 weeks
|
The PROMIS survey scores at 6 weeks postpartum |
6 weeks
|
|
WHOQoLBREF (World Health Organization Quality of Life Brief Version) survey score
Zeitfenster: 6 weeks
|
The WHOQoLBREF survey score at 6 weeks postpartum |
6 weeks
|
|
EQ-5D-3L1 (not an acronym) survey score
Zeitfenster: 6 weeks
|
The EQ-5D-3L1 survey score at 6 weeks postpartum |
6 weeks
|
|
PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System) survey score
Zeitfenster: 12 weeks
|
The PROMIS survey score at 12 weeks postpartum |
12 weeks
|
|
WHOQoLBREF (World Health Organization Quality of Life Brief Version) survey score
Zeitfenster: 12 weeks
|
The WHOQoLBREF survey score at 12 weeks postpartum |
12 weeks
|
|
EQ-5D-3L1 (not an acronym) survey score
Zeitfenster: 12 weeks
|
The EQ-5D-3L1 survey score at 12 weeks postpartum |
12 weeks
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Ronald George, MD, MOUNT SINAI HOSPITAL
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 23-03
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .